Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CASI CASI Pharmaceuticals	$2.43 +3.0%	$1.54	$1.09 ▼ $7.67	$29.89M	0.63	518,627 shs	109,006 shs
MAAQ Mana Capital Acquisition	$3.68 +1.1%	$3.92	$5.35 ▼ $10.25	$29.90M	N/A	33,075 shs	19,903 shs
MBIO Mustang Bio	$1.60 -3.3%	$1.73	$0.89 ▼ $21.95	$6.98M	2.22	2.52 million shs	95,519 shs
MURA Mural Oncology	$2.07 -0.7%	$2.27	$0.95 ▼ $4.74	$35.77M	3	1.98 million shs	424,694 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CASI CASI Pharmaceuticals	0.00%	-0.84%	+59.46%	+26.20%	-63.41%
MAAQ Mana Capital Acquisition	0.00%	+1.38%	-19.65%	-6.84%	+771.86%
MBIO Mustang Bio	0.00%	-6.78%	-13.61%	+32.00%	-91.18%
MURA Mural Oncology	0.00%	+18.18%	-14.05%	-24.36%	-39.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CASI CASI Pharmaceuticals	3.6973 of 5 stars	3.5	3.0	0.0	4.3	0.6	1.7	0.0
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	0.4365 of 5 stars	0.0	5.0	0.0	0.0	0.0	0.0	0.6
MURA Mural Oncology	2.9402 of 5 stars	3.3	3.0	0.0	0.0	1.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CASI CASI Pharmaceuticals	3.00	Buy	$4.00	63.87% Upside
MAAQ Mana Capital Acquisition	0.00	N/A	N/A	N/A
MBIO Mustang Bio	0.00	N/A	N/A	N/A
MURA Mural Oncology	2.50	Moderate Buy	$12.00	481.11% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CASI CASI Pharmaceuticals	$28.54M	1.05	N/A	N/A	$0.12 per share	20.34
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	($2.11) per share	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	$8.22 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CASI CASI Pharmaceuticals	-$39.26M	-$2.55	N/A	∞	N/A	-129.05%	-972.55%	-77.33%	8/29/2025 (Estimated)
MAAQ Mana Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	-$15.75M	-$78.00	N/A	N/A	N/A	N/A	N/A	-29.49%	11/6/2025 (Estimated)
MURA Mural Oncology	-$128.51M	-$8.59	N/A	N/A	N/A	N/A	-107.76%	-87.57%	11/12/2025 (Estimated)

Latest MBIO, MURA, MAAQ, and CASI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/29/2025	N/A	CASI CASI Pharmaceuticals	-$0.47	N/A	N/A	N/A	$6.28 million	N/A
8/8/2025	Q2 2025	MBIO Mustang Bio	N/A	-$0.19	N/A	-$0.19	N/A	N/A
8/4/2025	Q2 2025	MURA Mural Oncology	-$1.13	-$1.77	-$0.64	-$2.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MAAQ Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	N/A
MURA Mural Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CASI CASI Pharmaceuticals	N/A	0.81	0.68
MAAQ Mana Capital Acquisition	N/A	N/A	N/A
MBIO Mustang Bio	N/A	1.30	1.30
MURA Mural Oncology	N/A	2.87	2.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CASI CASI Pharmaceuticals	22.23%
MAAQ Mana Capital Acquisition	68.44%
MBIO Mustang Bio	9.95%
MURA Mural Oncology	80.21%

Insider Ownership

Company	Insider Ownership
CASI CASI Pharmaceuticals	21.24%
MAAQ Mana Capital Acquisition	N/A
MBIO Mustang Bio	0.21%
MURA Mural Oncology	2.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
MAAQ Mana Capital Acquisition	1	8.13 million	N/A	Not Optionable
MBIO Mustang Bio	100	4.38 million	7.23 million	Not Optionable
MURA Mural Oncology	119	17.32 million	16.94 million	Optionable

MBIO, MURA, MAAQ, and CASI Headlines

Recent News About These Companies

Advising XOMA Royalty on its Acquisition of Mural Oncology

August 22 at 7:50 AM | mhc.ieM

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

August 22 at 2:50 AM | pharmexec.comP

Mural Oncology to be acquired by XRA 5 Corp. for $2.035-$2.24 per share in cash

August 20, 2025 | msn.com

Xoma, a drug royalty specialist, buys another ‘zombie’ biotech

August 20, 2025 | finance.yahoo.com

MURA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mural Oncology plc Is Fair to Shareholders

August 20, 2025 | businesswire.com

Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share

August 20, 2025 | globenewswire.com

Two new murals installed in Downtown Peoria

August 19, 2025 | msn.com

From courtyard to connection: KGH welcomes a new healing mural

August 19, 2025 | interiorhealth.caI

Why some in Columbia cared so much about saving Hunter-Gatherer’s bricks & mural

August 14, 2025 | thestate.comT

Colourful mural celebrates 10 years of cancer care at WWL

August 4, 2025 | msn.com

Mural Oncology Announces Second Quarter Financial Results and Provides Business Update

August 4, 2025 | globenewswire.com

Artists help pupils and centre users create murals

August 3, 2025 | msn.com

Baltimore honors Henrietta Lacks with community-painted mural

August 2, 2025 | msn.com

Baltimore community comes together to complete Henrietta Lacks mural

August 2, 2025 | wmar2news.comW

Community news: Mural walk, health fair, digital skill lessons

July 28, 2025 | chicagotribune.com

New mural inspires student growth on the Eastern Shore

July 28, 2025 | msn.com

Downtown Raleigh’s history unfolds in a sprawling new mural. Who is on it?

July 28, 2025 | msn.com

Can Mural Oncology (NASDAQ:MURA) Afford To Invest In Growth?

July 23, 2025 | finance.yahoo.com

Minneapolis muralist honors Tuskegee airmen

July 19, 2025 | msn.com

Mural Oncology, Inc.: Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - FinanzNachrichten.de

July 8, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO, MURA, MAAQ, and CASI Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

$2.43 +0.07 (+2.97%)

Closing price 03:58 PM Eastern

Extended Trading

$2.48 +0.05 (+2.06%)

As of 04:04 PM Eastern

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Mana Capital Acquisition NASDAQ:MAAQ

$3.68 +0.04 (+1.10%)

As of 08/22/2025

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Mustang Bio NASDAQ:MBIO

$1.60 -0.06 (-3.33%)

Closing price 03:59 PM Eastern

Extended Trading

$1.53 -0.06 (-4.08%)

As of 04:04 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Mural Oncology NASDAQ:MURA

$2.06 -0.02 (-0.72%)

Closing price 03:58 PM Eastern

Extended Trading

$2.06 0.00 (-0.24%)

As of 04:03 PM Eastern

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time